Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells
Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 2001-02, Vol.413 (2), p.131-141 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 141 |
---|---|
container_issue | 2 |
container_start_page | 131 |
container_title | European journal of pharmacology |
container_volume | 413 |
creator | Tkaczyk-Gobis, Katarzyna Tarasiuk, Jolanta Seksek, Olivier Stefanska, Barbara Borowski, Edward Garnier-Suillerot, Arlette |
description | Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity of many natural cytotoxins. The influx and efflux of drugs across the cell membrane are in large part responsible for their intracellular concentrations, and in the search for new compounds able to overcome MDR, it is of prime importance to determine the molecular parameters whose modification would lead to an increase in the kinetics of uptake and/or to a decrease in the pump-mediated efflux. Here, we studied three members of a new family of benzoperimidine antitumor compounds which exhibit comparable cytotoxicity towards resistant cells expressing P-glycoprotein, or MRP1, and sensitive cells. We used spectrofluorometric methods to determine the kinetics of the uptake and release of these three drugs in different cell lines: the erythroleukemia cell line K562 and the resistant K562/Adr expressing P-glycoprotein, the small-cell lung cancer cell line GLC4 and resistant GLC4/Adr expressing MRP1. We also studied, using confocal microscopy, the intracellular distribution of these drugs in NIH/3T3 cells. Our data show that (i) the kinetics for the uptake of these drugs is very rapid, higher than 2×10
−17 mole cell
−1 s
−1, (ii) the drugs are strongly accumulated in the nucleus and lysosomes, (iii) the three drugs are recognized and pumped out by both transporters, as shown by the inhibition of P-glycoprotein- and MRP1-mediated efflux of pirarubicin by benzoperimidine, with inhibitory constants of 1.5 and 2.1 μM for P-glycoprotein and MRP1, respectively, suggesting that benzoperimidine is transported by the two transporters with
K
m∼2 μM. In conclusion, the fast uptake kinetics of the benzoperimidines counterbalance their efflux by P-glycoprotein and MRP1. |
doi_str_mv | 10.1016/S0014-2999(01)00728-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70651589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299901007282</els_id><sourcerecordid>70651589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-5bc83332160ff12fb707e7f6cc576281e85719e24bb9beb5088063f801cb0f23</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EotvCTwBZQkLlEBg7dWyfKlTxJVXiwN6t2BmDUWIH2wGVX0-yu2qPHEZzeebjfQh5weAtA9a9-wbArhqutb4E9gZActXwR2THlNQNSMYfk909ckbOS_kJAEJz8ZScMcZ516puR8o-97HMKVeaPI34h8YUG5dTKU3GEkrtY6VrhbpMKVOXpjktcSgbXn8gtRj_phlzmMIQIlLfT2G8oyHSaRlrGPLynT4scjiO5Rl54vux4PNTvyD7jx_2N5-b26-fvty8v21cq3RthHWqbVvOOvCecW8lSJS-c07IjiuGSkimkV9Zqy1aAUpB13oFzFnwvL0gr49r55x-LViqmULZHugjpqUYCZ1gQukVFEfwEDujN_Map893hoHZZJuDbLOZNMDMQbbZDrw8HVjshMPD1MnuCrw6AX1x_ehX1S6Ue06DEIKt1PWRwtXF74DZFBcwOhxCRlfNkMJ_HvkHtxudhg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70651589</pqid></control><display><type>article</type><title>Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tkaczyk-Gobis, Katarzyna ; Tarasiuk, Jolanta ; Seksek, Olivier ; Stefanska, Barbara ; Borowski, Edward ; Garnier-Suillerot, Arlette</creator><creatorcontrib>Tkaczyk-Gobis, Katarzyna ; Tarasiuk, Jolanta ; Seksek, Olivier ; Stefanska, Barbara ; Borowski, Edward ; Garnier-Suillerot, Arlette</creatorcontrib><description>Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity of many natural cytotoxins. The influx and efflux of drugs across the cell membrane are in large part responsible for their intracellular concentrations, and in the search for new compounds able to overcome MDR, it is of prime importance to determine the molecular parameters whose modification would lead to an increase in the kinetics of uptake and/or to a decrease in the pump-mediated efflux. Here, we studied three members of a new family of benzoperimidine antitumor compounds which exhibit comparable cytotoxicity towards resistant cells expressing P-glycoprotein, or MRP1, and sensitive cells. We used spectrofluorometric methods to determine the kinetics of the uptake and release of these three drugs in different cell lines: the erythroleukemia cell line K562 and the resistant K562/Adr expressing P-glycoprotein, the small-cell lung cancer cell line GLC4 and resistant GLC4/Adr expressing MRP1. We also studied, using confocal microscopy, the intracellular distribution of these drugs in NIH/3T3 cells. Our data show that (i) the kinetics for the uptake of these drugs is very rapid, higher than 2×10
−17 mole cell
−1 s
−1, (ii) the drugs are strongly accumulated in the nucleus and lysosomes, (iii) the three drugs are recognized and pumped out by both transporters, as shown by the inhibition of P-glycoprotein- and MRP1-mediated efflux of pirarubicin by benzoperimidine, with inhibitory constants of 1.5 and 2.1 μM for P-glycoprotein and MRP1, respectively, suggesting that benzoperimidine is transported by the two transporters with
K
m∼2 μM. In conclusion, the fast uptake kinetics of the benzoperimidines counterbalance their efflux by P-glycoprotein and MRP1.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(01)00728-2</identifier><identifier>PMID: 11226386</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>3T3 Cells - drug effects ; 3T3 Cells - metabolism ; Animals ; Antibiotics, Antineoplastic - pharmacology ; Antineoplastic agents ; Antineoplastic Agents - metabolism ; Antineoplastic Agents - pharmacology ; ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects ; ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism ; Benzoperimidine ; Biological and medical sciences ; Cell Nucleus - metabolism ; Chemotherapy ; DNA - metabolism ; Doxorubicin - analogs & derivatives ; Doxorubicin - pharmacology ; Drug Resistance, Multiple - physiology ; Drug Screening Assays, Antitumor - methods ; Genes, MDR - drug effects ; Genes, MDR - physiology ; Humans ; K562 Cells - drug effects ; K562 Cells - metabolism ; Lysosomes - metabolism ; Medical sciences ; Mice ; MRP1 (multidrug resistance-associated protein) ; Multidrug resistance ; P-glycoprotein ; Pharmacology. Drug treatments ; Quinazolines - chemistry ; Quinazolines - metabolism</subject><ispartof>European journal of pharmacology, 2001-02, Vol.413 (2), p.131-141</ispartof><rights>2001 Elsevier Science B.V.</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-5bc83332160ff12fb707e7f6cc576281e85719e24bb9beb5088063f801cb0f23</citedby><cites>FETCH-LOGICAL-c389t-5bc83332160ff12fb707e7f6cc576281e85719e24bb9beb5088063f801cb0f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0014299901007282$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=905551$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11226386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tkaczyk-Gobis, Katarzyna</creatorcontrib><creatorcontrib>Tarasiuk, Jolanta</creatorcontrib><creatorcontrib>Seksek, Olivier</creatorcontrib><creatorcontrib>Stefanska, Barbara</creatorcontrib><creatorcontrib>Borowski, Edward</creatorcontrib><creatorcontrib>Garnier-Suillerot, Arlette</creatorcontrib><title>Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity of many natural cytotoxins. The influx and efflux of drugs across the cell membrane are in large part responsible for their intracellular concentrations, and in the search for new compounds able to overcome MDR, it is of prime importance to determine the molecular parameters whose modification would lead to an increase in the kinetics of uptake and/or to a decrease in the pump-mediated efflux. Here, we studied three members of a new family of benzoperimidine antitumor compounds which exhibit comparable cytotoxicity towards resistant cells expressing P-glycoprotein, or MRP1, and sensitive cells. We used spectrofluorometric methods to determine the kinetics of the uptake and release of these three drugs in different cell lines: the erythroleukemia cell line K562 and the resistant K562/Adr expressing P-glycoprotein, the small-cell lung cancer cell line GLC4 and resistant GLC4/Adr expressing MRP1. We also studied, using confocal microscopy, the intracellular distribution of these drugs in NIH/3T3 cells. Our data show that (i) the kinetics for the uptake of these drugs is very rapid, higher than 2×10
−17 mole cell
−1 s
−1, (ii) the drugs are strongly accumulated in the nucleus and lysosomes, (iii) the three drugs are recognized and pumped out by both transporters, as shown by the inhibition of P-glycoprotein- and MRP1-mediated efflux of pirarubicin by benzoperimidine, with inhibitory constants of 1.5 and 2.1 μM for P-glycoprotein and MRP1, respectively, suggesting that benzoperimidine is transported by the two transporters with
K
m∼2 μM. In conclusion, the fast uptake kinetics of the benzoperimidines counterbalance their efflux by P-glycoprotein and MRP1.</description><subject>3T3 Cells - drug effects</subject><subject>3T3 Cells - metabolism</subject><subject>Animals</subject><subject>Antibiotics, Antineoplastic - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - metabolism</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects</subject><subject>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</subject><subject>Benzoperimidine</subject><subject>Biological and medical sciences</subject><subject>Cell Nucleus - metabolism</subject><subject>Chemotherapy</subject><subject>DNA - metabolism</subject><subject>Doxorubicin - analogs & derivatives</subject><subject>Doxorubicin - pharmacology</subject><subject>Drug Resistance, Multiple - physiology</subject><subject>Drug Screening Assays, Antitumor - methods</subject><subject>Genes, MDR - drug effects</subject><subject>Genes, MDR - physiology</subject><subject>Humans</subject><subject>K562 Cells - drug effects</subject><subject>K562 Cells - metabolism</subject><subject>Lysosomes - metabolism</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>MRP1 (multidrug resistance-associated protein)</subject><subject>Multidrug resistance</subject><subject>P-glycoprotein</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinazolines - chemistry</subject><subject>Quinazolines - metabolism</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EotvCTwBZQkLlEBg7dWyfKlTxJVXiwN6t2BmDUWIH2wGVX0-yu2qPHEZzeebjfQh5weAtA9a9-wbArhqutb4E9gZActXwR2THlNQNSMYfk909ckbOS_kJAEJz8ZScMcZ516puR8o-97HMKVeaPI34h8YUG5dTKU3GEkrtY6VrhbpMKVOXpjktcSgbXn8gtRj_phlzmMIQIlLfT2G8oyHSaRlrGPLynT4scjiO5Rl54vux4PNTvyD7jx_2N5-b26-fvty8v21cq3RthHWqbVvOOvCecW8lSJS-c07IjiuGSkimkV9Zqy1aAUpB13oFzFnwvL0gr49r55x-LViqmULZHugjpqUYCZ1gQukVFEfwEDujN_Map893hoHZZJuDbLOZNMDMQbbZDrw8HVjshMPD1MnuCrw6AX1x_ehX1S6Ue06DEIKt1PWRwtXF74DZFBcwOhxCRlfNkMJ_HvkHtxudhg</recordid><startdate>20010216</startdate><enddate>20010216</enddate><creator>Tkaczyk-Gobis, Katarzyna</creator><creator>Tarasiuk, Jolanta</creator><creator>Seksek, Olivier</creator><creator>Stefanska, Barbara</creator><creator>Borowski, Edward</creator><creator>Garnier-Suillerot, Arlette</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010216</creationdate><title>Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells</title><author>Tkaczyk-Gobis, Katarzyna ; Tarasiuk, Jolanta ; Seksek, Olivier ; Stefanska, Barbara ; Borowski, Edward ; Garnier-Suillerot, Arlette</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-5bc83332160ff12fb707e7f6cc576281e85719e24bb9beb5088063f801cb0f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>3T3 Cells - drug effects</topic><topic>3T3 Cells - metabolism</topic><topic>Animals</topic><topic>Antibiotics, Antineoplastic - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - metabolism</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects</topic><topic>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</topic><topic>Benzoperimidine</topic><topic>Biological and medical sciences</topic><topic>Cell Nucleus - metabolism</topic><topic>Chemotherapy</topic><topic>DNA - metabolism</topic><topic>Doxorubicin - analogs & derivatives</topic><topic>Doxorubicin - pharmacology</topic><topic>Drug Resistance, Multiple - physiology</topic><topic>Drug Screening Assays, Antitumor - methods</topic><topic>Genes, MDR - drug effects</topic><topic>Genes, MDR - physiology</topic><topic>Humans</topic><topic>K562 Cells - drug effects</topic><topic>K562 Cells - metabolism</topic><topic>Lysosomes - metabolism</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>MRP1 (multidrug resistance-associated protein)</topic><topic>Multidrug resistance</topic><topic>P-glycoprotein</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinazolines - chemistry</topic><topic>Quinazolines - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tkaczyk-Gobis, Katarzyna</creatorcontrib><creatorcontrib>Tarasiuk, Jolanta</creatorcontrib><creatorcontrib>Seksek, Olivier</creatorcontrib><creatorcontrib>Stefanska, Barbara</creatorcontrib><creatorcontrib>Borowski, Edward</creatorcontrib><creatorcontrib>Garnier-Suillerot, Arlette</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tkaczyk-Gobis, Katarzyna</au><au>Tarasiuk, Jolanta</au><au>Seksek, Olivier</au><au>Stefanska, Barbara</au><au>Borowski, Edward</au><au>Garnier-Suillerot, Arlette</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2001-02-16</date><risdate>2001</risdate><volume>413</volume><issue>2</issue><spage>131</spage><epage>141</epage><pages>131-141</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>Multidrug resistance (MDR) phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or multidrug resistance-associated protein (MRP1). Both proteins are energy-dependent drug efflux pumps that efficiently reduce the intracellular accumulation and hence the cytotoxicity of many natural cytotoxins. The influx and efflux of drugs across the cell membrane are in large part responsible for their intracellular concentrations, and in the search for new compounds able to overcome MDR, it is of prime importance to determine the molecular parameters whose modification would lead to an increase in the kinetics of uptake and/or to a decrease in the pump-mediated efflux. Here, we studied three members of a new family of benzoperimidine antitumor compounds which exhibit comparable cytotoxicity towards resistant cells expressing P-glycoprotein, or MRP1, and sensitive cells. We used spectrofluorometric methods to determine the kinetics of the uptake and release of these three drugs in different cell lines: the erythroleukemia cell line K562 and the resistant K562/Adr expressing P-glycoprotein, the small-cell lung cancer cell line GLC4 and resistant GLC4/Adr expressing MRP1. We also studied, using confocal microscopy, the intracellular distribution of these drugs in NIH/3T3 cells. Our data show that (i) the kinetics for the uptake of these drugs is very rapid, higher than 2×10
−17 mole cell
−1 s
−1, (ii) the drugs are strongly accumulated in the nucleus and lysosomes, (iii) the three drugs are recognized and pumped out by both transporters, as shown by the inhibition of P-glycoprotein- and MRP1-mediated efflux of pirarubicin by benzoperimidine, with inhibitory constants of 1.5 and 2.1 μM for P-glycoprotein and MRP1, respectively, suggesting that benzoperimidine is transported by the two transporters with
K
m∼2 μM. In conclusion, the fast uptake kinetics of the benzoperimidines counterbalance their efflux by P-glycoprotein and MRP1.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>11226386</pmid><doi>10.1016/S0014-2999(01)00728-2</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2001-02, Vol.413 (2), p.131-141 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_70651589 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | 3T3 Cells - drug effects 3T3 Cells - metabolism Animals Antibiotics, Antineoplastic - pharmacology Antineoplastic agents Antineoplastic Agents - metabolism Antineoplastic Agents - pharmacology ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism Benzoperimidine Biological and medical sciences Cell Nucleus - metabolism Chemotherapy DNA - metabolism Doxorubicin - analogs & derivatives Doxorubicin - pharmacology Drug Resistance, Multiple - physiology Drug Screening Assays, Antitumor - methods Genes, MDR - drug effects Genes, MDR - physiology Humans K562 Cells - drug effects K562 Cells - metabolism Lysosomes - metabolism Medical sciences Mice MRP1 (multidrug resistance-associated protein) Multidrug resistance P-glycoprotein Pharmacology. Drug treatments Quinazolines - chemistry Quinazolines - metabolism |
title | Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T10%3A22%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transport%20of%20new%20non-cross-resistant%20antitumor%20compounds%20of%20the%20benzoperimidine%20family%20in%20multidrug%20resistant%20cells&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Tkaczyk-Gobis,%20Katarzyna&rft.date=2001-02-16&rft.volume=413&rft.issue=2&rft.spage=131&rft.epage=141&rft.pages=131-141&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(01)00728-2&rft_dat=%3Cproquest_cross%3E70651589%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70651589&rft_id=info:pmid/11226386&rft_els_id=S0014299901007282&rfr_iscdi=true |